On December 20, 2024, the National Medical Products Administration (NMPA) granted conditional approval for the marketing of Talrectinib Adipate Capsules (brand name: Dabole), a Category 1 innovative drug declared by Boyuan Biomedical Technology (Hangzhou) Co., Ltd., through its priority review and approval procedure.
This medication is indicated for adult patients with ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have experienced disease progression following treatment with ROS1 tyrosine kinase inhibitors (ROS1-TKIs), providing a new treatment option for these patients.
